AIDS, In Molecular pathomechanisms and new trends in drug research.

Birch C. 2002.
Taylor and Francis Group.

The role of resistance testing in clinical practice.

Birch C. 2002.
ASHM Journal Club 11:41-44.

The use of the laboratory in the diagnosis and management of HIV infection.

Birch C, and Dwyer D. 2002.
In: Management of the HIV-infected patient. Martin Dunitz Ltd, London.

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.

Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, and Trautwein C. 2002.
Gastroenterology 122:264-73.

Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.

Bonacini M, Kurz A, Locarnini S, Ayres A, and Gibbs C. 2002.
Gastroenterology 122:244-5.

Viral dynamics.

Bowden D, and Lewin S. 2002.
Microbiology Australia 23:12-13.

Recent infection with HIV in Victoria 1999 – 2000 determined by “Detuned” EIA.

Breschkin A, Enriquez A, and Catton MC. 2002.
Victorian Infectious Diseases Bulletin 5:20-22.

Importation of measles virus into Australia.

Catton M, and Chibo D. 2002.
Microbiology Australia 23:20-22.

Emerging therapies of hepatitis B and C.

Chen RY, Desmond PV, and Locarnini SA. 2002.
J Gastroenterol Hepatol 17:S471-81.

Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.

Chibo D, Mijch A, Doherty R, and Birch C. 2002.
J Clin Virol 25:165.

Novel measles virus genotype, East Timor and Australia.

Chibo D, Riddell M, Catton MC, and Birch C. 2002.
Emerg Infect Dis 8:735-7.

The use of dried blood spots to detect antibodies to hepatitis C virus.

Christofis P, Breschkin A, Lee JY, Catton M, Pierce L, Bradshaw C, and Wood V. 2002.
Victorian Infectious Diseases Bulletin 5:41-42.

Chronic Strongyloides stercoralis infection in Laotian immigrants and refugees 7-20 years after resettlement in Australia.

de Silva S, Saykao P, Kelly H, MacIntyre CR, Ryan N, Leydon J, and Biggs B. 2002.
Epidemiology and Infection 128:439-444.

Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro.

Delaney WE, Edwards R, Colledge D, Shaw T, Furman P, Painter G, and Locarnini S. 2002.
Antimicrob Agents Chemother 46:3057-60.

Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome.

Dev AT, McCaw R, Sundararajan V, Bowden S, and Sievert W. 2002.
Hepatology 36:1259-65.

Utility of a multiplex PCR assay for detecting herpesvirus DNA in clinical samples.

Druce J, Catton M, Chibo D, Minerds K, Tyssen D, Kostecki R, Maskill B, Leong-Shaw W, Gerrard M, and Birch C. 2002.
J Clin Microbiol 40:1728-32.

Antiviral therapy for hepatitis B virus infections: new targets and technical challenges.

Feld J, and Locarnini S. 2002.
J Clin Virol 25:267-83.

Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.

Glenn MP, Pattenden LK, Reid RC, Tyssen DP, Tyndall JD, Birch CJ, and Fairlie DP. 2002.
J Med Chem 45:371-81.

Two summer outbreaks of influenza A in aged-care facilities in Victoria.

Guy R, Di Natale R, Tobin S, Robinson P, Kelly H, and Hampson A. 2002.
Victorian Infectious Diseases Bulletin 5:4.

Apparent improvement in surveillance for cases of acute flaccid paralysis in Australia.

Kelly H, and Brussen KA. 2002.
Aust N Z J Public Health 26:281-2.

Serum alanine aminotransferase levels and the detection of hepatitis C virus (HCV) in chronic HCV infections.

Kelly HA, Maskill WJ, Sievert W, and Bowden DS. 2002.
Med J Aust 176:139.

Measles transmission in the health care setting (editorial).

Kelly H, Riddell M, and Andrews RM. 2002.
Med J Aust 176:50-51.

A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia.

Kelly H, Riddell M, Gidding H, Nolan T, and Gilbert G. 2002.
Vaccine 20:3130-3136.

Studies in progress: acute flaccid paralysis.

Kelly H, Thorley BR, Brussen KA, Antony J, Elliott E, and Morris A. 2002.
2001 Ninth Annual Report. Australian Paediatric Surveillance Unit.

Measles transmission in healthcare settings in Australia.

Kelly HA, Riddell MA, and Andrews RM. 2002.
Med J Aust 176:50-1.

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, Locarnini S, and Liang R. 2002.
Hepatology 36:702-9.

Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies.

Lewin S, Walters T, and Locarnini S. 2002.
Antiviral Res 55:381-96.

Evolving therapies for the treatment of chronic hepatitis B virus infection.

Locarnini S, Bartholomeusz A, and Delaney WE. 2002.
Expert opinion on investigational drugs:169-187.

Clinical relevance of viral dynamics and genotypes in hepatitis B virus.

Locarnini SA. 2002.
J Gastroenterol Hepatol 17:S322-S328.

Mechanisms of drug resistance and novel approaches to therapy for chronic hepatitis C.

Locarnini SA. 2002.
J Gastroenterol Hepatol 17 Suppl 3:S351-S359.

Advances in hepatitis C: what is coming in the next 5 years?

Locarnini SA, and Bartholomeusz A. 2002.
J Gastroenterol Hepatol 17:442-7.

Evolving therapies for the treatment of chronic hepatitis B virus infection.

Locarnini SA, Bartholomeusz A, and Delaney WE. 2002.
Expert Opin Investig Drugs 11:169-87.

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Lok AS, Zoulim F, Locarnini S, Mangia A, Niro G, Decraemer H, Maertens G, Hulstaert F, De Vreese K, and Sablon E. 2002.
J Clin Microbiol 40:3729-34.

Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2000: report of the Australian Mycobacterium Laboratory Reference Network.

Lumb R, Bastian I, Dawson D, Gilpin C, Havekort F, Howard P, Sievers A, and A. M. L. R. Network. 2002.
Commun Dis Intell 26:226-233.

Electron microscope identification of poxvirus in clinical samples in Victoria 1997 – 2001.

Marshall JA. 2002.
Victorian Infectious Diseases Bulletin 5:5-6.

Mixed infections of intestinal viruses and bacteria in humans., p. 299-316.

Marshall JA. 2002.
K. Brogden and J. Guthmiller (ed.), In Polymicrobial Diseases, vol. Chapter 15. ASM Press, Washington D.C.

High level excretion of Norwalk-like virus following resolution of clinical illness.

Marshall JA, Salamone S, Yuen LK, Catton M, and Wright P. 2002.
Infectious Diseases Review Journal. 2:12-13.

Detection of measles virus-specific immunoglobulin M in dried venous blood samples by using a commercial enzyme immunoassay.

Riddell MA, Leydon JA, Catton MG, and Kelly HA. 2002.
J Clin Microbiol 40:5-9.

Editorial: Norwalk-like virus – issues for surveillance.

Roche P, Marshall JA, and Spencer J. 2002.
Commun Dis Intell 26:552-554.

Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints.

Shaw T, Bowden S, and Locarnini S. 2002.
Gastroenterology 123:2135-40.

The conformation of the mature dimeric human immunodeficiency virus type 1 RNA genome requires packaging of pol protein.

Shehu-Xhilaga M, Hill M, Marshall JA, Kappes J, Crowe SM, and Mak J. 2002.
J Virol 76:4331-40.

Overexpression and incorporation of Gag Pol precursor does not impede packaging of HIV-1 tRNALys3 but promotes intracellular budding of virus-like particles.

Shehu-Xhilaga M, Lee JY, Campbell S, Marshall JA, Crowe SM, and Mak J. 2002.
Journal of Biomedical Science 9:697-705.

Prevalence of hepatitis G/GBV-C in a Healthy Paediatric Population.

Siebert DJ, Bowden DS, Tracy SL, and Hardikar W. 2002.
J Paediatr Child Health 38:423.

Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C- infected patients with beta thalassemia major.

Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, and Locarnini S. 2002.
Am J Gastroenterol 97:982-7.

Trial of the ICT Malaria Pf/Pv(TM). Immunographic test in the diagnosis of P. falciparim and P. vivax in Vietnam.

Thanh N, Karunajeeva H, Biggs BA, Kim T, Manitta J, Huong M, Jolley D, Hipgrave D, and Cony D. 2002.
Transactions of Royal Society of Trop. Med. & Hyg.

Annual report of the Australian National Poliovirus Reference Laboratory and summary of acute flaccid paralysis surveillance, 2001.

Thorley BR, Brussen KA, Stambos V, Yuen LK, and Kelly HA. 2002.
Commun Dis Intell 26:419-27.

Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the “fingers” subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.

Torresi J, Earnest-Silveira L, Civitico G, Walters TE, Lewin SR, Fyfe J, Locarnini SA, Manns M, Trautwein C, and Bock TC. 2002.
Virology 299:88-99.

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy.

Torresi J, Earnest-Silveira L, Deliyannis G, Edgtton K, Zhuang H, Locarnini SA, JFyfe, Sozzi T, and Jackson DC. 2002.
Virology 293:305-13.

Influenza vaccine effectiveness in people aged 65 years and over living in the community: a meta-analysis.

Vu T, Farish S, Jenkins M, and Kelly H. 2002.
Vaccine 20:1831-1836.

Fragmentation of influenza surveillance in Australia.

Watts C, and Kelly H. 2002.
Commun Dis Intell 26:8-13.